New York State Common Retirement Fund cut its holdings in Albany Molecular Research, Inc. (NASDAQ:AMRI) by 76.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,000 shares of the biotechnology company’s stock after selling 83,752 shares during the quarter. New York State Common Retirement Fund owned approximately 0.06% of Albany Molecular Research worth $564,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in AMRI. Municipal Employees Retirement System of Michigan boosted its stake in Albany Molecular Research by 5.8% in the second quarter. Municipal Employees Retirement System of Michigan now owns 5,260 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 290 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Albany Molecular Research by 69.8% in the second quarter. BNP Paribas Arbitrage SA now owns 7,044 shares of the biotechnology company’s stock valued at $153,000 after buying an additional 2,895 shares in the last quarter. Thrivent Financial For Lutherans boosted its stake in Albany Molecular Research by 5.4% in the first quarter. Thrivent Financial For Lutherans now owns 12,640 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 650 shares in the last quarter. Round Table Services LLC acquired a new stake in Albany Molecular Research in the second quarter valued at about $205,000. Finally, ING Groep NV acquired a new stake in Albany Molecular Research in the second quarter valued at about $220,000. 72.10% of the stock is currently owned by institutional investors and hedge funds.

Shares of Albany Molecular Research, Inc. (AMRI) opened at $21.74 on Friday. Albany Molecular Research, Inc. has a 12 month low of $13.01 and a 12 month high of $22.17. The company has a current ratio of 0.68, a quick ratio of 0.37 and a debt-to-equity ratio of 0.62.

Separately, BidaskClub lowered Albany Molecular Research from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Five investment analysts have rated the stock with a hold rating, The company has an average rating of “Hold” and a consensus price target of $18.00.

COPYRIGHT VIOLATION NOTICE: “Albany Molecular Research, Inc. (AMRI) Shares Sold by New York State Common Retirement Fund” was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/albany-molecular-research-inc-amri-shares-sold-by-new-york-state-common-retirement-fund/1697386.html.

Albany Molecular Research Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.